Selpercatinib Drug Asset Due Diligence Report 2026

This Selpercatinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Selpercatinib can convert its Small molecule drug profile and RET biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Selpercatinib (query alias: selpercatinib)
Modality / target	Small molecule drug; RET; RET inhibitors
Highest global status	Approved
Originator	Loxo Oncology, Inc.
Active developers	Eli Lilly & Co., Lilly Asia Shanghai Representative Office, Loxo Oncology, Inc.

The MCP disease footprint includes RET fusion-positive Solid Tumors, metastatic non-small cell lung cancer, Metastatic Solid Tumor. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07010393	Phase 4	Not yet recruiting	335	Real-World Progression-Free Survival (rwPFS)
NCT07146893	Early Phase 1	Not yet recruiting	7	Mean (± SD) changes in body weight after 12 weeks
NCT06532149	Not Applicable	Recruiting	80	Incidence of treatment-related sexual dysfuction in male patients with ANSCLC

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Selpercatinib in Early-Stage <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Phase 3; n=151; evaluation: Positive. Reported fields: EFS(2-year; stage IB, II, or IIIA disease; investigator-assessed) = 70.0 % ; EFS(2-year; stage IB, II, or IIIA disease; investigator-assessed) = 94.0 %

Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.

Phase 3; n=151; evaluation: Positive. Reported fields: EFS(2-year) = 61.1 % ; EFS(2-year) = 91.5 %

61P - Treatment patterns and outcomes of patients with RET fusion-positive non-small cell lung cancer (NSCLC) treated with selpercatinib in Europe: Final results from the SPRINT-RET study

Not Applicable; n=52; evaluation: Positive. Reported fields: Adenocarcinomas = 96.2 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Selpercatinib addresses RET fusion-positive Solid Tumors, metastatic non-small cell lung cancer, Metastatic Solid Tumor. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-03-28	Innovent and Lilly Expand Strategic Partnership in Oncology	Approved	US$45.0M upfront
2019-01-07	Lilly Completes Acquisition of Loxo Oncology	NDA/BLA	US$8,000.0M stated total
2013-07-10	Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement	Not disclosed	US$434.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “RET gene fusions and uses thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO